Bionews, Inc.’s Post

I’m truly inspired by Bionews’ new product, “The Rare Journey.” 🌟 This immersive platform offers a deep dive into the patient experience. It’s a catalyst for pharma and healthcare companies seeking to develop more effective support and services. And, the potential for sponsorships in this space is incredibly exciting. I love how they’ve blended compassion, creativity, and technology to create such a powerful impact. Check out this unique exploration of life with rare diseases. #healthcareinnovation #patientcentric #raredisease #biotech #innovation #Bionews #patientcentric #raredisease #patientengagement

🎥 2024: The Road to Production: As we gear up for production in the coming months, we're reminded that every share, discussion, and bit of support counts. Our mission with "TOXSICK" is to create a documentary that not only tells a compelling story but also initiates meaningful change in healthcare systems worldwide. 🤝 𝐒𝐞𝐞𝐤𝐢𝐧𝐠 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐬: In this critical phase, we're actively looking for the right partners and collaborators. Whether you're a healthcare expert, a seasoned filmmaker, a passionate advocate, a leader in the world of business / marketing, or someone with a unique perspective, your insights are invaluable to us. 🌍 𝐓𝐡𝐞 𝐌𝐢𝐬𝐬𝐢𝐨𝐧 𝐨𝐟 𝐓𝐎𝐗𝐒𝐈𝐂𝐊: Our goal is to unveil the profound impact of a prescription medicine, highlighting the untold stories and advocating for the most vulnerable, including the neurodivergent, LGBTQIA+ communities, and women - all of whom have historically been underserved by our healthcare systems. Through this journey, TOXSICK aspires to be more than a documentary – it's a beacon of hope, illuminating paths towards a better, safer, more inclusive future in healthcare. 🌐 𝐁𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐚𝐧𝐝 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐂𝐡𝐚𝐧𝐠𝐞: By sharing our flyers and spreading the word about TOXSICK, you're not just supporting a film; you're part of a movement to reshape healthcare perspectives and practices. Tag anyone you know who's passionate about making a real impact through documentaries and storytelling. Individually we can make great things, together, we can move mountains. 💬𝐆𝐞𝐭 𝐢𝐧 𝐓𝐨𝐮𝐜𝐡: If you're interested in being part of TOXSICK, we'd love to connect. Reach out to us and join a growing group of like-minded individuals and organisations dedicated to creating a more equitable healthcare future. 📩𝐒𝐭𝐚𝐲 𝐔𝐩𝐝𝐚𝐭𝐞𝐝 - 𝐉𝐨𝐢𝐧 𝐎𝐮𝐫 𝐌𝐚𝐢𝐥𝐢𝐧𝐠 𝐋𝐢𝐬𝐭: For the latest updates on TOXSICK, visit 𝐰𝐰𝐰.𝐭𝐨𝐱𝐬𝐢𝐜𝐤.𝐨𝐫𝐠, and subscribe to our mailing list. Be the first to know about our progress and opportunities to get involved. #DocumentaryFilm, #HealthcareReform, #MentalHealthAwareness, #PatientAdvocacy, #SocialImpact

Clearly, ScribeNote is barking up the right tree. Check out this story right meow. https://lnkd.in/dA9suUV7

Viagra's Hard Lessons: Why Understanding the Patient Journey is Non-Negotiable with Annabel de Maria Bosch This was the title my team came up with when they listened to my last conversation with Annabel. She is courageous, experienced, and empathetic and this helped her to navigate an extremely complicated situation when Viagra was starting on the market. She and her team found out that by using the patient journey you can turn things around and create the success story that Viagra is today 🚀 🚀 🚀 This is only one of the many stories she shared so listen to our conversation in the comments or on Trials with Maya Z 🤗 #viagra #patientfirst #patientengagement #clinicaltrials #patientjourney

We are inspired by Dr. Fabrizio Mancini wisdom and we are sure you will be too! 🌟 'Success is about getting uncomfortable until you get comfortable.' Now's your chance to take control of your media journey with Vettify. 🚀 Click the link - bit.ly/VetwithDrFab and let's make an impact together! #BookedAndBlessed #MediaReady #Vettify #mediareadinessforinfluencer #getmediaready

Got questions about navigating the tricky waters of vet med culture and team dynamics? Well, Andi has the answers you’re looking for! Submit your questions on enhancing clinic culture, mastering communication, or leading with empathy. No query is too big or too small. Together, let’s explore solutions and unlock possibilities. ✨ Submit your questions to Ask Andi - because together, we flourish. #AskAndi 🔗 https://buff.ly/3n31zS2

Our DeviceTalks Boston messaging is resonating! This is going to make my job easier for the next few weeks! Thanks Joe Mullings for the breather and The Mullings Group for the support!! 💪 💪 Interested in attending?! Make sure you use the code mentioned in this short clip! #DTBOSTON2024 #medtech #medicaldevices #medicaldevice

We can’t stop thinking about International Unicorn 🦄 Day either!! Let us reintroduce Charley the Christie Unicorn! He is our fearless mascot. Wish Charley a happy Unicorn Day in the comments below! #PIVC #VeinVisualization #HealthcareInnovation #christiemed #veinviewer #charlietheunicorn #internationalunicornday

Very few founders are equipped to take their company from ideation to exit, especially if the company makes it to full blown commercial launch. Even less are capable of taking the organization public, and scaling it appropriately. In truth, the same is true of any C-Suite role in a Med Tech start-up. Think about this....how many Founders have we seen do in Med Tech what Elon Musk, Jeff Bezos, and Mark Zuckerberg were able to do in Tech? While I am sure there are other examples, Reinhold Schmieding of Arthrex is the only one that comes to mind. The point is, it's beyond rare. In an early stage start up, one of the surest signs of success is when the company outgrows the Founder and the initial leadership team. This is not a negative thing. It means the team did what they set out to do, build a burgeoning company. At some point, the time usually comes to hand over the reigns to someone more well equipped to take the company to new heights. With so much at stake: Why does this happen so often with little to no planning? Why is a successor seldom identified long before the transition takes place? Why do BOD's, typically dominated at that point by career financiers/venture capital types, so often vote against the wishes of the outgoing CEO, and appoint a successor of their choosing? Why are world renowned CEO/Executive Coaches (such as the Bernie Haffey) seldom retained to ensure a smooth transition for the outgoing CEO, a fast start for the incoming CEO, and to assist the executive team members in processing the transition? Will you be at DeviceTalks Boston? If so, this will be a can't miss session around an all too seldom planned for event, CEO succession. And Senior Partner at The Mullings Group, Holly Scott is the perfect person to carry the dialogue.

Dheeraj Talreja, Senior Vice President of Marketing and Commercial Strategy at Freenome, spotlights how community engagement is central to both our approach and our core values at Freenome. As he states, "When one launches a new product, one should launch with the community. Not at them. At Freenome, we listen and learn from patient groups, from providers. We ask, 'How should we bring our products to you?' We could never launch a product alone; it will always be in partnership. By doing this, we earn the trust of the patient communities we serve." This philosophy is critical to Freenome's mission. We strive to ensure that our research and product development are rooted in the needs and perspectives of the communities we aim to serve. #CommunityEngagement #PatientCentric #EarlyCancerDetection